AOD-9604
A growth hormone fragment that targets fat loss without the side effects of HGH
This is the pharmaceutical-grade version of the HGH fat-loss fragment, developed by Monash University in Australia. Scientists took the part of human growth hormone that handles fat metabolism and isolated it into its own compound. The result is a peptide that tells fat cells to break down and stop forming new fat — without any of the blood sugar, fluid retention, or growth-related side effects that come with using full HGH. It went through Phase IIb clinical trials for obesity, which gives it more human safety data than many research peptides.
Mechanism of action
AOD-9604 binds to receptors on fat cells that control whether fat is stored or burned. When it activates these receptors, fat cells release their stored fat into the bloodstream to be used as energy. It also blocks the process that turns immature fat cells into mature, fat-storing ones. Because it does not bind to the main HGH receptor, it completely bypasses the growth-promoting and blood-sugar-disrupting effects of full growth hormone. It is essentially a precision tool for fat metabolism.
Benefits discussed in research
- Stimulates lipolysis (fat breakdown) without affecting blood sugar
- Inhibits lipogenesis (new fat formation)
- Does not affect IGF-1 levels, avoiding growth-related side effects
- May support cartilage and bone repair
- Potential anti-aging properties
- Well-tolerated with a favorable safety profile
Research status
Phase II
Dosing information
For educational and research purposes only. Not medical advice.
- typical
- 300 mcg per day
- range
- 200–600 mcg per day
- frequency
- Once daily, ideally in the morning on an empty stomach
- route
- Subcutaneous injection or oral
- cycleLength
- 12–16 weeks
- notes
- Administer in a fasted state for best results. Oral bioavailability is lower than injection but still effective. Combine with a caloric deficit and exercise for optimal fat loss results.
Side effects and safety
- Mild injection site redness
- Headache (rare)
- Nausea (rare)
- Generally very well tolerated
Frequently asked questions
Is AOD-9604 the same as HGH Fragment 176-191?
They are very similar but not identical. Both are fragments of human growth hormone that target fat metabolism. AOD-9604 is the pharmaceutical-grade version developed by Monash University, with a slightly different structure and more clinical research behind it. Think of HGH Fragment 176-191 as the raw research version and AOD-9604 as the refined, better-studied version.
Will AOD-9604 affect my insulin sensitivity?
No, and this is one of its biggest advantages. Full HGH can raise blood sugar and reduce insulin sensitivity, which is a real concern for long-term use. AOD-9604 does not bind to the main HGH receptor, so it completely bypasses those effects. Your blood sugar and insulin response stay normal.
Research references
- AOD9604 Phase IIb Clinical Trial for Obesity (2006)
- Metabolic Effects of AOD9604 in Obese Subjects (2001)
Related peptides
- Semaglutide
The breakthrough GLP-1 agonist for sustainable weight loss
- Tesamorelin
FDA-approved GHRH analog for visceral fat reduction
- CJC-1295
A long-acting GHRH analog for sustained growth hormone release
- 5-Amino-1MQ
NNMT inhibitor that promotes fat oxidation inside adipocytes without appetite suppression